Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SOLSTICE: Trifluridine/Tipiracil + Bevacizumab vs Capecitabine + Bevacizumab in 1L Metastatic Colorectal Cancer
NCT03869892Phase 3Active, not recruiting
- Sponsor
- Servier
- Start
- Mar 2019
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 25
01
Overview
Phase 3, randomised, open-label trial of trifluridine + tipiracil in metastatic colorectal cancer (mCRC) (2 arms), sponsored by Servier. Primary endpoint: Progression-free Survival at 24 months. Started Mar 2019; status: active, not recruiting.
02
Drugs
trifluridine + tipiracil
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT03869892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03869892.